Search Results - "Ecca, Fabrizio"
-
1
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
Published in Biomedicine & pharmacotherapy (01-10-2022)“…Preemptive targeted pharmacogenetic testing of candidate variations in DPYD is currently being used to limit toxicity associated with fluoropyrimidines. The…”
Get full text
Journal Article -
2
Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
Published in Cells (Basel, Switzerland) (01-10-2019)“…Carboplatin/paclitaxel is the reference regimen in the treatment of advanced high-grade serous ovarian cancer (HGSOC) in neo-adjuvant chemotherapy (NACT)…”
Get full text
Journal Article -
3
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity
Published in American journal of human genetics (06-06-2019)“…Fluoropyrimidines (FLs) have been widely used for more than 60 years against a range of solid tumors and still remains the cornerstone for the treatment of…”
Get full text
Journal Article -
4
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation
Published in Drug resistance updates (01-07-2018)“…Adverse events affect the pharmacological treatment of approximately 90% of colorectal cancer (CRC) patients at any stage of the disease. Chemotherapy…”
Get full text
Journal Article -
5
Immunogenetics of prostate cancer: a still unexplored field of study
Published in Pharmacogenomics (01-02-2018)“…The immune system is a double-edged sword with regard to the prostate cancer (PCa) battle. Immunogenetics, the study of the potential role of immune-related…”
Get full text
Journal Article -
6
Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects
Published in Journal of cellular physiology (01-09-2019)“…Peptidyl‐prolyl cis–trans isomerase, NIMA‐interacting 1 (PIN1) is a peptidyl‐prolyl isomerase that binds phospho‐Ser/Thr‐Pro motifs in proteins and catalyzes…”
Get full text
Journal Article -
7
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice
Published in Clinical pharmacology and therapeutics (01-04-2019)“…Lack of information on the clinical utility of preemptive DPYD screening before fluoropyrimidine treatment is a major barrier preventing its use in clinical…”
Get full text
Journal Article -
8
The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
Published in Cancer drug resistance (01-01-2019)“…Fluoropyrimidines (FP) are given in the combination treatment of the advanced disease or as monotherapy in the neo-adjuvant and adjuvant treatment of…”
Get full text
Journal Article -
9